Malawi, Ethiopia and Indonesia are leading the way

For the first time in 2020 the new 3HP regimen for prevention of TB will be taken into the TB programs of high TB burden countries with Malawi, Ethiopia and Indonesia among the first, all three supported by KNCV Tuberculosis Foundation (KNCV).

This improved treatment for TB infection is now accessible to a far greater number of people at high risk for the disease. This is a critical, life saving intervention for people living with HIV (PLHIV) and people who are exposed to infectious, airborne TB. These developments were made possible due to the Unitaid-funded IMPAACT4TB-project, implemented by a consortium led by the Aurum Institute. KNCV is the implementer in four of the 12 project countries, joining a group of six countries which are leading the way.

The 3HP treatment is especially relevant for PLHIV. It’s easier to take than previously used treatments, with less side effects and better results and can be used in combination with the latest anti-retroviral treatments.

The goal of the project IMPAACT4TB, – which stand for: Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB – is to reduce TB incidence and deaths among PLHIV and child contacts through sustainable implementation of affordable, quality-assured 3HP.

3HP is a short-course regimen of isoniazid and rifapentine weekly for three months for treatment of LTBI. The outcomes of the project are to: increase the number of PLHIV and child contacts starting treatment with affordable, quality-assured 3HP; and contribute to revising WHO preventive therapy management guidelines based on evidence generated from this project.

 

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Address

KNCV Tuberculosefonds
Maanweg 174
2516 AB Den Haag
+31 70 416 7222

OPEN IN GOOGLE MAPS

Postal address

Postbus 146
2501 CC Den Haag

More information

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.